Cipla Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
1563.80 -7.65 (-0.49%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1551.45
Today’s High
1573
52 Week Low
1132
52 Week High
1702
1562.20 -9.55 (-0.61%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1550.4
Today’s High
1573
52 Week Low
1132
52 Week High
1702.05
Key Metrics
- Market Cap (In Cr) 126933.8
- Beta 0.43
- Div. Yield (%) 0.83
- P/B 4.75
- TTM P/E 27.78
- Peg Ratio 3.56
- Sector P/E 36.27
- D/E -
- Open Price 1564.85
- Prev Close 1571.45
Cipla Analysis
Price Analysis
-
1 Week-4.2%
-
3 Months4.06%
-
6 Month14.29%
-
YTD26.11%
-
1 Year34.98%
Risk Meter
- 23% Low risk
- 23% Moderate risk
- 23% Balanced Risk
- 23% High risk
- 23% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 4
- 4
- 4
- 7
- Buy
- 13
- 13
- 12
- 12
- Hold
- 8
- 8
- 8
- 5
- Sell
- 5
- 5
- 5
- 4
- Strong Sell
- 2
- 2
- 2
- 2
- Total
- 32
- 32
- 31
- 30
Cipla News
Buy or sell: Vaishali Parekh recommends three stocks to buy today — October 10
2 min read . 10 Oct 2024Over 180 stocks hit one-year highs while Sensex falls; investors earn ₹3 lakh Cr
2 min read . 09 Oct 2024Cipla Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 25774.09
- Selling/ General/ Admin Expenses Total
- 4310.04
- Depreciation/ Amortization
- 1051.02
- Other Operating Expenses Total
- 6353.43
- Total Operating Expense
- 20728.88
- Operating Income
- 5045.21
- Net Income Before Taxes
- 5701.9
- Net Income
- 4121.55
- Diluted Normalized EPS
- 52.77
- Period
- 2024
- Total Assets
- 32717.82
- Total Liabilities
- 6011.39
- Total Equity
- 26706.43
- Tangible Book Valueper Share Common Eq
- 272.4
- Period
- 2024
- Cashfrom Operating Activities
- 4133.91
- Cashfrom Investing Activities
- -2988.03
- Cashfrom Financing Activities
- -1200.43
- Net Changein Cash
- -48.99
- Period
- 2023
- Total Revenue
- 22753.12
- Selling/ General/ Admin Expenses Total
- 7507.04
- Depreciation/ Amortization
- 1017.83
- Other Operating Expenses Total
- 511.6
- Total Operating Expense
- 19047.03
- Operating Income
- 3706.09
- Net Income Before Taxes
- 4038.35
- Net Income
- 2801.91
- Diluted Normalized EPS
- 37.37
- Period
- 2023
- Total Assets
- 29463.28
- Total Liabilities
- 6055.5
- Total Equity
- 23407.78
- Tangible Book Valueper Share Common Eq
- 234.08
- Period
- 2023
- Cashfrom Operating Activities
- 3237.65
- Cashfrom Investing Activities
- -2388.51
- Cashfrom Financing Activities
- -958.29
- Net Changein Cash
- -96.78
- Period
- 2022
- Total Revenue
- 21763.34
- Selling/ General/ Admin Expenses Total
- 6908.86
- Depreciation/ Amortization
- 987.83
- Other Operating Expenses Total
- 463.91
- Total Operating Expense
- 18430.6
- Operating Income
- 3332.74
- Net Income Before Taxes
- 3493.27
- Net Income
- 2516.75
- Diluted Normalized EPS
- 33.28
- Period
- 2022
- Total Assets
- 27101.12
- Total Liabilities
- 6259.43
- Total Equity
- 20841.69
- Tangible Book Valueper Share Common Eq
- 198.32
- Period
- 2022
- Cashfrom Operating Activities
- 3325.9
- Cashfrom Investing Activities
- -1871.88
- Cashfrom Financing Activities
- -1599.79
- Net Changein Cash
- -132.32
- Period
- 2021
- Total Revenue
- 19159.59
- Selling/ General/ Admin Expenses Total
- 6031.69
- Depreciation/ Amortization
- 1000.57
- Other Operating Expenses Total
- 399.33
- Total Operating Expense
- 15960.05
- Operating Income
- 3199.54
- Net Income Before Taxes
- 3290.06
- Net Income
- 2404.87
- Diluted Normalized EPS
- 30.35
- Period
- 2021
- Total Assets
- 25151.89
- Total Liabilities
- 6825.36
- Total Equity
- 18326.53
- Tangible Book Valueper Share Common Eq
- 167.29
- Period
- 2021
- Cashfrom Operating Activities
- 3755.2
- Cashfrom Investing Activities
- -2387.18
- Cashfrom Financing Activities
- -1329.9
- Net Changein Cash
- 50.91
- Period
- 2020
- Total Revenue
- 17131.99
- Selling/ General/ Admin Expenses Total
- 6203.89
- Depreciation/ Amortization
- 1097.31
- Other Operating Expenses Total
- 421.32
- Total Operating Expense
- 15091.19
- Operating Income
- 2040.8
- Net Income Before Taxes
- 2178.18
- Net Income
- 1546.52
- Diluted Normalized EPS
- 19.8
- Period
- 2020
- Total Assets
- 23662.56
- Total Liabilities
- 7899.56
- Total Equity
- 15763
- Tangible Book Valueper Share Common Eq
- 135.56
- Period
- 2020
- Cashfrom Operating Activities
- 3068.45
- Cashfrom Investing Activities
- 104.04
- Cashfrom Financing Activities
- -2948.82
- Net Changein Cash
- 234.02
- Period
- 2019
- Total Revenue
- 16362.41
- Selling/ General/ Admin Expenses Total
- 5710.55
- Depreciation/ Amortization
- 1095.66
- Other Operating Expenses Total
- 495.46
- Total Operating Expense
- 14585.29
- Operating Income
- 1777.12
- Net Income Before Taxes
- 2079.14
- Net Income
- 1527.7
- Diluted Normalized EPS
- 20.97
- Period
- 2019
- Total Assets
- 23963.32
- Total Liabilities
- 8951.04
- Total Equity
- 15012.28
- Tangible Book Valueper Share Common Eq
- 127.03
- Period
- 2019
- Cashfrom Operating Activities
- 1691.14
- Cashfrom Investing Activities
- -1668.68
- Cashfrom Financing Activities
- -348.72
- Net Changein Cash
- -345.11
- Period
- 2024-06-30
- Total Revenue
- 6693.94
- Selling/ General/ Admin Expenses Total
- 1194.23
- Depreciation/ Amortization
- 246.68
- Other Operating Expenses Total
- 1591.03
- Total Operating Expense
- 5224.82
- Operating Income
- 1469.12
- Net Income Before Taxes
- 1611.36
- Net Income
- 1177.64
- Diluted Normalized EPS
- 14.57
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 6163.24
- Selling/ General/ Admin Expenses Total
- 1084.23
- Depreciation/ Amortization
- 288.34
- Other Operating Expenses Total
- 1713.03
- Total Operating Expense
- 5135.72
- Operating Income
- 1027.52
- Net Income Before Taxes
- 1259.26
- Net Income
- 939.04
- Diluted Normalized EPS
- 11.62
- Period
- 2024-03-31
- Total Assets
- 32717.82
- Total Liabilities
- 6011.39
- Total Equity
- 26706.43
- Tangible Book Valueper Share Common Eq
- 272.4
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 4133.91
- Cashfrom Investing Activities
- -2988.03
- Cashfrom Financing Activities
- -1200.43
- Net Changein Cash
- -48.99
- Period
- 2023-12-31
- Total Revenue
- 6603.81
- Selling/ General/ Admin Expenses Total
- 1068.13
- Depreciation/ Amortization
- 233.43
- Other Operating Expenses Total
- 1568.62
- Total Operating Expense
- 5284.53
- Operating Income
- 1319.28
- Net Income Before Taxes
- 1473.81
- Net Income
- 1055.9
- Diluted Normalized EPS
- 14.82
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 6678.15
- Selling/ General/ Admin Expenses Total
- 1091.1
- Depreciation/ Amortization
- 290.04
- Other Operating Expenses Total
- 1540.21
- Total Operating Expense
- 5234.44
- Operating Income
- 1443.71
- Net Income Before Taxes
- 1594.23
- Net Income
- 1130.91
- Diluted Normalized EPS
- 14
- Period
- 2023-09-30
- Total Assets
- 31377.09
- Total Liabilities
- 6551.69
- Total Equity
- 24825.4
- Tangible Book Valueper Share Common Eq
- 252.21
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 1688.51
- Cashfrom Investing Activities
- -741.85
- Cashfrom Financing Activities
- -708.18
- Net Changein Cash
- 237.77
- Period
- 2023-06-30
- Total Revenue
- 6328.89
- Selling/ General/ Admin Expenses Total
- 1066.58
- Depreciation/ Amortization
- 239.21
- Other Operating Expenses Total
- 1531.57
- Total Operating Expense
- 5074.19
- Operating Income
- 1254.7
- Net Income Before Taxes
- 1374.6
- Net Income
- 995.7
- Diluted Normalized EPS
- 12.33
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 5739.3
- Selling/ General/ Admin Expenses Total
- 964.84
- Depreciation/ Amortization
- 346.22
- Other Operating Expenses Total
- 1537.35
- Total Operating Expense
- 5094.2
- Operating Income
- 645.1
- Net Income Before Taxes
- 745.37
- Net Income
- 525.65
- Diluted Normalized EPS
- 8.1
- Period
- 2023-03-31
- Total Assets
- 29463.28
- Total Liabilities
- 6055.5
- Total Equity
- 23407.78
- Tangible Book Valueper Share Common Eq
- 234.08
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 3237.65
- Cashfrom Investing Activities
- -2388.51
- Cashfrom Financing Activities
- -958.29
- Net Changein Cash
- -96.78
- Period
- 2022-12-31
- Total Revenue
- 5810.09
- Selling/ General/ Admin Expenses Total
- 948.69
- Depreciation/ Amortization
- 272.11
- Other Operating Expenses Total
- 1449.55
- Total Operating Expense
- 4674.65
- Operating Income
- 1135.44
- Net Income Before Taxes
- 1218.06
- Net Income
- 800.96
- Diluted Normalized EPS
- 9.92
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Cipla Technical
Moving Average
SMA
- 5 Day1627.05
- 10 Day1635.64
- 20 Day1643.49
- 50 Day1611.83
- 100 Day1556.63
- 300 Day1476.04
Cipla Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Sun Pharmaceutical Industries
- 1896.35
- -1.15
- -0.06
- 1960.2
- 1069
- 454997.89
- Divis Laboratories
- 6130.4
- 23.05
- 0.38
- 6276.2
- 3300
- 162742.86
- Cipla
- 1563.8
- -7.65
- -0.49
- 1702
- 1132
- 126260.43
- Torrent Pharmaceuticals
- 3505.7
- 8.3
- 0.24
- 3589.95
- 1822.8
- 118653.92
- Dr Reddys Laboratories
- 6709.6
- 91.7
- 1.39
- 7101
- 5212.1
- 111733.95
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Sun Pharmaceutical Industries
- 45.76
- 7.2
- 11.27
- 14.23
- Divis Laboratories
- 102.93
- 12.16
- 18.97
- 26.38
- Cipla
- 29.73
- 4.83
- 13.5
- 12.66
- Torrent Pharmaceuticals
- 73.67
- 17.23
- 20.64
- 13.18
- Dr Reddys Laboratories
- 20.16
- 3.93
- 16.73
- 14.63
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 29-Oct-24
- Quarterly Results
- 26-Jul-24
- Quarterly Results
- 10-May-24
- Audited Results & Final Dividend
- 25-Jan-24
- Quarterly Results
- 22-Jan-24
- Quarterly Results
- 27-Oct-23
- Quarterly Results
- 26-Jul-23
- Quarterly Results
- 12-May-23
- Audited Results & Final Dividend
- 25-Jan-23
- Quarterly Results
- 04-Nov-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 20-Aug-24
- 10-May-24
- AGM
- 10-Aug-23
- 12-May-23
- AGM
- 26-Aug-22
- 29-Jul-22
- AGM
- 25-Aug-21
- 27-Jul-21
- AGM
- 27-Mar-21
- 23-Feb-21
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 10-May-24
- 02-Aug-24
- 02-Aug-24
- 13
- 12-May-23
- 21-Jul-23
- 21-Jul-23
- 8.5
- 27-Jul-22
- 10-Aug-22
- 08-Aug-22
- 5
- 14-May-21
- -
- 09-Aug-21
- 5